drugset
drugset / Trial / NCT04260698

Expanded Access of Omidubicel, for Allogeneic Transplantation in Patients With Hematological Malignancies

NCT04260698 ↗

Phase 3 Completed 36 enrolled Gamida Cell ltd
NaSingle-groupOpen-labelTreatment

Summary

Omidubicel is an investigational therapy for patients with high-risk hematologic malignancies.

Timeline

Start
2020-07-08
Primary completion
2025-05-08
Completion
2025-05-08

Drugs

EvaluationDrugModalityDoseRoute
Subject omidubicel Cell therapy — —

Indications

hematopoietic and lymphoid cell neoplasm